Momenta Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference

        Print
| Source: Momenta Pharmaceuticals

CAMBRIDGE, Mass., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Canaccord Genuity 33rd Annual Growth Conference will be webcast on Wednesday, August 14 at 2:30 p.m. ET.

The audio webcast of the presentation will be available live on the "Investors" section of the company's website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event and will be available for two weeks following the presentation.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel drugs.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Lora Pike
Momenta Pharmaceuticals, Inc.

617.395.5189